Pakistan is set to transform its pharmaceutical sector with the introduction of a nationwide digital verification system for medicines. The federal cabinet has approved a comprehensive track and trace mechanism that will help authorities monitor medicines from production to the point of sale, reducing the risk of counterfeit and substandard drugs entering the market.
The initiative is being viewed as a major advancement in the country’s healthcare and regulatory framework. By leveraging digital technology, the government aims to enhance transparency across the pharmaceutical supply chain and strengthen public confidence in the quality of medicines available in Pakistan.
Federal Health Minister Syed Mustafa Kamal announced that the cabinet has also approved amendments to the Drug Labelling and Packing Rules, 1978. These regulatory changes are considered essential for the successful implementation of the new tracking and verification system nationwide.
According to the health minister, every medicine produced, imported, distributed, and sold in Pakistan will gradually become part of a digitally monitored network. This system will allow authorities to trace the movement of pharmaceutical products throughout the supply chain and verify their authenticity at various stages.
The introduction of a track and trace framework is expected to significantly improve efforts to eliminate fake medicines. Counterfeit drugs have remained a persistent challenge in many markets, often posing serious risks to patient health and safety. Such products may contain incorrect ingredients, insufficient active compounds, or substances that can be harmful to consumers.
Under the new system, each medicine package will carry a unique digital identity that can be tracked and verified. This will make it easier for regulators to identify suspicious products, investigate supply chain irregularities, and remove unauthorized medicines from circulation before they reach patients.
The digital monitoring initiative is also expected to improve accountability among pharmaceutical manufacturers, distributors, wholesalers, and retailers. With greater visibility into the movement of medicines, regulatory bodies will be better equipped to enforce compliance and ensure industry standards are maintained.
Healthcare experts have long advocated for stronger monitoring systems to address the growing threat of counterfeit medicines. The adoption of digital verification technology aligns Pakistan with international best practices that have already been implemented in several countries to improve medicine safety and supply chain integrity.
In addition to protecting consumers, the system could help streamline regulatory processes and provide valuable data for policymakers. Real-time tracking capabilities may enable authorities to identify shortages, monitor distribution patterns, and respond more effectively to healthcare challenges.
The government’s decision reflects a broader commitment to modernizing Pakistan’s healthcare infrastructure through technology-driven solutions. As implementation progresses, pharmaceutical companies and healthcare stakeholders will be required to adapt to new compliance requirements and digital reporting standards.
The nationwide track and trace system marks an important step toward ensuring that patients receive genuine, safe, and high-quality medicines. By strengthening oversight and increasing transparency, Pakistan aims to create a more secure pharmaceutical ecosystem that benefits both consumers and the healthcare industry.